JAZZ News and Press, Jazz Pharmaceuticals plc From 03/12/20

Allakos (NASDAQ: ALLK ) initiated with Underperform rating and $34 (42% downside risk) price target at SMBC Nikko. More news on: Allakos Inc., Avadel Pharmaceuticals plc, Krystal Biotech, Inc., Healthcare stocks news, Stocks on the move, , Read more ...

Quick Take NLS Pharmaceutics ( NLSP ) has filed to raise $40.25 million in an IPO of its common stock, according to an F-1 registration statement . The company is advancing a pipeline of drug candidates for the treatment of various central nervous system disorders. NLSP expects to begin...

Who doesn't love a good sale? With the markets in turmoil and little idea when it will end, healthcare investors can seize the opportunity to snap up discounted shares of quality companies. Here, I explore six attractive small and mid-cap biotechs with valuations greater than $5.5 billion. Thes...

The Magic Formula by Joel Greenblatt has been a subject of my writing in the past . What used to bug me is that the screen included many microcaps and odd stocks such as royalty trusts. Therefore I decided to set the minimum market cap at $2.5bn. Overall, I am pleased with the new result be...

Jazz Pharmaceuticals Provides Mixed Results and Updates Jazz Pharmaceuticals ( JAZZ ) reported its fourth-quarter and full-year results and the numbers looked mixed. The company’s GAAP net income for the year stood at $523.4 million, up from $447.1 million it had earned for the pr...

The following slide deck was published by Jazz Pharmaceuticals plc in conjunction with their 2019 Q4 earnings Read more ...

Jazz Pharmaceuticals plc (JAZZ) Q4 2019 Results Earnings Conference Call February 26, 2020, 04:30 PM ET Company Participants Katherine Littrell - Vice President, Investor Relations Bruce Cozadd - Chairman and Chief Executive Officer Daniel Swisher, Jr. - President and Chief Opera...

Jazz Pharmaceuticals (NASDAQ: JAZZ ) -1.8% reports Q4 beats with revenue up 22% Y/Y. The mixed FY20 outlook sees revenue of $2.32-2.4B (consensus: $2.32B) and EPS of $12.50-13.40 (consensus: $17.05). More news on: Jazz Pharmaceuticals plc, Healthcare stocks news, ...

Jazz Pharmaceuticals (NASDAQ: JAZZ ): Q4 Non-GAAP EPS of $4.42 beats by $0.30 ; GAAP EPS of $1.29 misses by $0.20 . Revenue of $581.74M (+22.1% Y/Y) beats by $21.16M . Shares +0.2% . Press Release More news on: Jazz Pharmaceuticals plc, Earnings news and commentary, Healthcare ...

DUBLIN , Feb. 25, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the full year and the fourth quarter of 2019 and provided financial guidance for 2020. "With more than $2 billion of revenue and double-digit top- and bottom-li...